First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study.

Huang, L-Y; Chang, H-P; Chang, R-Y; Tai, H-Y; Huang, Y-W; Lee, P-C

Huang, L-Y; Chang, H-P; Chang, R-Y; Tai, H-Y; Huang, Y-W; Lee, P-C.

Affiliation

Huang LY; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan. lyhuang277@cde.org.tw.

Eur Rev Med Pharmacol Sci ; 26(20): 7632-7640, 2022 10.

Article in En | MEDLINE | ID: mdl-36314347

Subject(s)

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Humans; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/genetics; Cohort Studies; Lung Neoplasms/drug therapy; Lung Neoplasms/genetics; Retrospective Studies; ErbB Receptors/genetics; ErbB Receptors/therapeutic use; Mutation; Protein Kinase Inhibitors/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Eur Rev Med Pharmacol Sci Journal subject: FARMACOLOGIA / TOXICOLOGIA Year: 2022 Type: Article Affiliation country: Taiwan

Fulltext

XML

PubMed Links

Search on Google